As of April 22, 2026, Avalo Therapeutics's top three insider holders are Garry Arthur Neil (Chief Executive Officer, 90.11K shares), Garry Arthur Neil (Chief Executive Officer, 90.11K shares), Christopher Ryan Sullivan (Chief Financial Officer, 17.34K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Capital Management Ltd. Caissa | - | 0 | 5,772 | 30 May, 2023 |
| Capital Management Ltd. Caissa | - | 0 | 5,772 | 30 May, 2023 |
| Capital, Llc Armistice | - | 0 | 3,048 | 28 Jun, 2023 |
| Garry Arthur Neil | Chief Executive Officer | 90,114 | 0 | 31 Mar, 2026 |
| Garry Arthur Neil | Chief Executive Officer | 90,114 | 0 | 31 Mar, 2026 |
| James Archie Jr Harrell | Chief Commercial Officer | 153 | 0 | 14 Dec, 2021 |
| James Archie Jr Harrell | Chief Commercial Officer | 153 | 0 | 14 Dec, 2021 |
| H Jeffrey Wilkins | Chief Medical Officer | 139 | 0 | 14 Dec, 2021 |
| H Jeffrey Wilkins | Chief Medical Officer | 139 | 0 | 14 Dec, 2021 |
| Christopher Ryan Sullivan | Chief Financial Officer | 17,338 | 0 | 03 Apr, 2026 |
| Christopher Ryan Sullivan | Chief Financial Officer | 17,338 | 0 | 03 Apr, 2026 |
| Aaron Kantoff | - | 6,333 | 0 | 31 Mar, 2026 |
| Mitchell Chan | - | 6,333 | 0 | 31 Mar, 2026 |
| Aaron Kantoff | - | 6,333 | 0 | 31 Mar, 2026 |
| Samantha Truex | - | 6,333 | 0 | 31 Mar, 2026 |
| Mitchell Chan | - | 6,333 | 0 | 31 Mar, 2026 |
| Samantha Truex | - | 6,333 | 0 | 31 Mar, 2026 |
| Schond L. Greenway | Cfo | 16 | 0 | 14 Dec, 2021 |
| Schond L. Greenway | Cfo | 16 | 0 | 14 Dec, 2021 |
| Paul Varki | Chief Legal Officer | 3,634 | 0 | 12 Dec, 2025 |
| Paul Varki | Chief Legal Officer | 3,634 | 0 | 12 Dec, 2025 |
| Mittie Doyle | Chief Medical Officer | 3,622 | 0 | 08 Apr, 2026 |
| June Sherie Almenoff | - | 3,167 | 0 | 01 Apr, 2025 |
| Jonathan Goldman | - | 3,166 | 0 | 31 Mar, 2026 |
| Jonathan Goldman | - | 3,166 | 0 | 31 Mar, 2026 |
| Jennifer Riley | Chief Strategy Officer | 2,655 | 0 | 12 Dec, 2025 |
| Jennifer Riley | Chief Strategy Officer | 2,655 | 0 | 12 Dec, 2025 |
| June Sherie Almenoff | - | 0 | 1,000 | 14 Nov, 2024 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Apr, 2026 | Mittie Doyle | Common Stock | A | 3,970 | $12.65 | 7,592 | D | M |
| 06 Apr, 2026 | Mittie Doyle | Common Stock | D | 3,970 | $18.01 | 3,622 | D | S |
| 06 Apr, 2026 | Mittie Doyle | Stock Option (Right to Buy) | D | 3,970 | $0.00 | 210,530 | D | M |
| 01 Apr, 2026 | Mittie Doyle | Common Stock | A | 679 | $8.04 | 4,301 | D | M |
| 01 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 500 | $15.86 | 32,797 | D | S |
| 01 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 500 | $15.86 | 32,797 | D | S |
| 01 Apr, 2026 | Mittie Doyle | Common Stock | D | 679 | $16.00 | 3,622 | D | S |
| 01 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 7,479 | $16.83 | 25,318 | D | S |
| 01 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 7,479 | $16.83 | 25,318 | D | S |
| 02 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 6,200 | $17.02 | 19,118 | D | S |
| 02 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 6,200 | $17.02 | 19,118 | D | S |
| 01 Apr, 2026 | Mittie Doyle | Stock Option (Right to Buy) | D | 679 | $0.00 | 148,329 | D | M |
| 02 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 1,780 | $17.57 | 17,338 | D | S |
| 02 Apr, 2026 | Christopher Ryan Sullivan | Common Stock | D | 1,780 | $17.57 | 17,338 | D | S |
| 31 Mar, 2026 | Rita Jain | Stock Option (Right to Buy) | A | 1,339 | $12.13 | 1,339 | D | A |
| 31 Mar, 2026 | Kevin Robert Lind | Stock Option (Right to Buy) | A | 1,370 | $12.13 | 1,370 | D | A |
| 31 Mar, 2026 | Rita Jain | Stock Option (Right to Buy) | A | 1,339 | $12.13 | 1,339 | D | A |
| 31 Mar, 2026 | Kevin Robert Lind | Stock Option (Right to Buy) | A | 1,370 | $12.13 | 1,370 | D | A |
| 28 Mar, 2026 | Samantha Truex | Common Stock | A | 3,166 | - | 6,333 | D | M |
| 28 Mar, 2026 | Aaron Kantoff | Common Stock | A | 3,166 | - | 6,333 | D | M |